Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
In the SURMOUNT-1 trial, tirzepatide produced dose-dependent weight reductions, with average losses approaching or exceeding ~20% at higher doses in adults with obesity who did not have diabetes, numbers that markedly exceed historical pharmacotherapy benchmarks
Benefits Are Stepping Up Aons 2025 U.S
Further research, including long-term evaluation of sarcopenia in GLP-1RAs trials, development of standardized monitoring protocols and investigation of combined nutritional, exercise and pharmacologic strategies, is needed in order to prevent muscle loss while maximizing metabolic benefits under GLP-1RAs treatment
These organizations ensure they have obtained all necessary rights, consents, approvals, and authority to share data with TriNetX under a Business Associate Agreement, provided their identity remains anonymous and the data is used solely for research purposes
In the as treated (AT) approach, the observation was stopped in case patients discontinued treatment with GLP-1RA or BI
